A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma
Year: 2024
Type: article
Study design: Clinical Trial
Source: Targeted Oncology
Authors: Jifang Gong, Ye Guo, Yanqiao Zhang, Yi Ba, Tong Chen, Wei Li, Caicun Zhou, Mengzhao Wang, Haiyan Yang, Yuhong Zhou, Qiqing Cai, Ziping Wang, Gang Huang, Wei Zhang, Rila Su, Zhongheng Cai, Zenglian Yue, Jinzhou Dou, Peiqi Li, Rachel Wu, Archie N. Tse, Lin Shen
Institutions: Peking University Cancer Hospital, Tongji University, Shanghai East Hospital, Third Affiliated Hospital of Harbin Medical University, Tianjin Medical University Cancer Institute and Hospital, Fudan University, Huashan Hospital, First Hospital of Jilin University, Shanghai Pulmonary Hospital, Peking Union Medical College Hospital, Zhejiang Cancer Hospital, Zhongshan Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, First Affiliated Hospital of Nanchang University, CStone Pharmaceuticals (China)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4402217003